Citius Pharmaceuticals (NASDAQ:CTXR) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Citius Pharmaceuticals (NASDAQ:CTXR) released its earnings results on Friday. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.05), Zacks reports.

Citius Pharmaceuticals Stock Down 0.4 %

NASDAQ:CTXR opened at $2.69 on Friday. The stock’s 50-day simple moving average is $3.17 and its 200 day simple moving average is $8.85. Citius Pharmaceuticals has a twelve month low of $2.44 and a twelve month high of $26.75.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Citius Pharmaceuticals in a research note on Tuesday, January 7th.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.